Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.84 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.72 |
| ▸ | MGLL | Q99685 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476619 | 1.00 | HSD11B1 (0.84) | HSD11B1SLC18A3MGLLNPC1RAB9A | |
| SCHEMBL5468364 | 0.94 | HSD11B1 (0.82) | HSD11B1SLC18A3MGLLKDM4EPOLB | |
| SCHEMBL5468368 | 0.94 | HSD11B1 (0.82) | HSD11B1SLC18A3MGLLKDM4EPOLB | |
| SCHEMBL21928849 | 0.92 | HSD11B1 (0.71) | HSD11B1SLC18A3MGLLNPC1RAB9A | |
| SCHEMBL1720014 | 0.92 | HSD11B1 (1.00) | HSD11B1SLC18A3MGLLKDM4EPOLB | |
| SCHEMBL1719734 | 0.91 | MGLL (0.68) | HSD11B1SLC18A3MGLLMEN1KMT2A | |
| SCHEMBL5472341 | 0.88 | MGLL (0.85) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL5472343 | 0.88 | MGLL (0.85) | HSD11B1MGLLKDM4EPOLBGAA | |
| SCHEMBL1720091 | 0.86 | MGLL (0.84) | HSD11B1MGLLMEN1KMT2A | |
| SCHEMBL5474311 | 0.86 | HSD11B1 (0.68) | HSD11B1SLC18A3MGLLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | claimed |
| EP-1685101-A1 | N-ACYLATED-3-(BENZOYL)-PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005047250-A1 | N-ACYLATED-3- (BENZOYL) - PYRROLIDINES AS 11-BETA-HSD1 INHIBITORS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS. | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | HSD11B1 2026/4885SLC18A3 2864/4885MGLL 3022/4885 |
| US-20070219266-A1 | N-Acylated-3-(Benzoyl)-Pyrrolidines as 11-Beta-HSD1 Inhibitors Useful for the Treatment of Metabolic Disorders | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SLC18A3 4355/4885MGLL 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.